How to optimise treatment in EGFR-mutant NSCLC
Targeted therapies improve outcomes in EGFR-mutant NSCLC, with studies like MARIPOSA showing amivantamab plus lazertinib reduces resistance mechanisms. MARIPOSA-2 highlights amivantamab plus chemotherapy's survival benefits post-osimertinib. Zipalertinib shows promise for EGFR exon 20 insertion-mutated NSCLC, indicating a move towards personalised, precision-guided treatment approaches.
Reference News
Targeted therapies improve outcomes in EGFR-mutant NSCLC, with studies like MARIPOSA showing amivantamab plus lazertinib reduces resistance mechanisms. MARIPOSA-2 highlights amivantamab plus chemotherapy's survival benefits post-osimertinib. Zipalertinib shows promise for EGFR exon 20 insertion-mutated NSCLC, indicating a move towards personalised, precision-guided treatment approaches.